Researchers in biotech, academia and Big Pharma are offering puzzle pieces to crack CAR-T for solid tumors. Will they ever snap together?

The idea seemed promising enough.

By the time a group of scientists reported an attempt to treat colon cancer with engineered T cells drawn from patients, expanded and armed with artificial surface proteins in 2010, the experimental therapy — known as CAR-T, short for chimeric antigen receptor transduced T cells...

Click to view original post